View ValuationCore Laboratories 향후 성장Future 기준 점검 2/6Core Laboratories은 연간 수입과 매출이 각각 18.3%와 2.5% 증가할 것으로 예상되고 EPS는 연간 18.5%만큼 증가할 것으로 예상됩니다.핵심 정보18.3%이익 성장률18.51%EPS 성장률Energy Services 이익 성장7.8%매출 성장률2.5%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트18 May 2026최근 향후 성장 업데이트공시 • Mar 24+ 1 more updateCore Laboratories Inc. Revises Earnings Guidance for the First Quarter 2026Core Laboratories Inc. revised earnings guidance for the first quarter 2026 . Company continues to evaluate and monitor the evolving geopolitical conflict in the Middle East and its effect on the Company's first quarter 2026 financial results. Core Lab is working with clients and its local teams to manage operations and mitigate impacts on project execution through a rapidly changing operating environment. The safety and security of the Company's employees remain its highest priority. At this time, due to regional instability, including client-driven project delays, travel constraints, and supply-chain disruptions, the Company expects first quarter 2026 revenue and earnings to be below its previously issued guidance provided on February 4, 2026. Changes in client activity levels across the Middle East are directly impacting operations in the countries where Core Lab operates. Damage to oil refining infrastructure and storage terminals has created capacity limitations, forcing operators to shut in or limit oil production. These effects have extended to regional supply chains and the maritime transportation of crude oil and refined products—particularly through the Strait of Hormuz—resulting in logistical constraints and delays in project execution. The impact has been more pronounced in Reservoir Description due to its unique role in supporting regional client studies, crude oil assay testing, and reservoir rock and fluid characterization, all of which rely on predictable field access, sample movement, and laboratory operations. Production Enhancement has been comparatively less affected; however, shipments of energetics products into certain parts of the region have been delayed or temporarily suspended. Core's revised guidance for first quarter 2026 revenue ranges from $119,000,000to $123,000,000, while operating income, ex-items, is projected to range from $5,700,000to $7,100,000. The Company is now projecting Earnings Per Share, ex-items, to be between $0.05 to $0.07 for the first quarter of 2026.공시 • Oct 23+ 1 more updateCore Laboratories Inc. Announces Earnings Guidance for Fourth Quarter 2025Core Laboratories Inc. announced earnings guidance for fourth quarter 2025. For the quarter, revenue is projected to range from $132,000,000 to $136,000,000, with operating income of $14,000,000 to $16,100,000, yielding operating margins of approximately 11%. EPS for the fourth quarter of 2025 is expected to be $0.18 to $0.22.공시 • Jan 30+ 1 more updateCore Laboratories Inc. Provides Earnings Guidance for the First Quarter 2025Core Laboratories Inc. provided earnings revenue for the first quarter 2025. The Company's first quarter 2025 revenue is projected to range from $121,000,000 to $127,000,000, with operating income of $10,200,000 to $12,800,000, yielding operating margins of approximately 9%. As such, EPS for the first quarter of 2025 is expected to be $0.12 to $0.16.공시 • Oct 24+ 1 more updateCore Laboratories Inc. Provides Earnings Guidance for the Fourth Quarter of 2024Core Laboratories Inc. provided earnings guidance for the fourth quarter of 2024. The company’s fourth quarter 2024 revenue is projected to range from $128,500,000 to $135,500,000, with operating income of $14,800,000 to $17,700,000, yielding operating margins of approximately 12%. EPS for the fourth quarter of 2024 is expected to be $0.20 to $0.25.공시 • Nov 02+ 1 more updateCore Laboratories Inc. Provides Consolidated Earnings Guidance for the Fourth Quarter of 2023Core Laboratories Inc. provided consolidated earnings guidance for the fourth quarter of 2023. The company's fourth quarter 2023 revenue is projected to range from $125,000,000 to $132,000,000 and operating income of $13,800,000 to $17,300,000, yielding operating margins of approximately 12%. EPS for the fourth quarter of 2023 is expected to be $0.17 to $0.23. The Company's fourth quarter 2023 guidance is based on projections for underlying operations and excludes gains and losses in foreign exchange.모든 업데이트 보기Recent updates공시 • May 02Core Laboratories Inc. Approves Cash Dividend, Payable on June 1, 2026Core Laboratories Inc. announced on April 29, 2026, the Board approved a cash dividend of $0.01 per share of common stock, payable on June 1, 2026, to shareholders of record on May 11, 2026.공시 • Apr 01Core Laboratories Inc., Annual General Meeting, May 12, 2026Core Laboratories Inc., Annual General Meeting, May 12, 2026. Location: hotel zaza, memorial city, 9787 katy freeway, texas 77024, houston, United States공시 • Mar 24+ 1 more updateCore Laboratories Inc. Revises Earnings Guidance for the First Quarter 2026Core Laboratories Inc. revised earnings guidance for the first quarter 2026 . Company continues to evaluate and monitor the evolving geopolitical conflict in the Middle East and its effect on the Company's first quarter 2026 financial results. Core Lab is working with clients and its local teams to manage operations and mitigate impacts on project execution through a rapidly changing operating environment. The safety and security of the Company's employees remain its highest priority. At this time, due to regional instability, including client-driven project delays, travel constraints, and supply-chain disruptions, the Company expects first quarter 2026 revenue and earnings to be below its previously issued guidance provided on February 4, 2026. Changes in client activity levels across the Middle East are directly impacting operations in the countries where Core Lab operates. Damage to oil refining infrastructure and storage terminals has created capacity limitations, forcing operators to shut in or limit oil production. These effects have extended to regional supply chains and the maritime transportation of crude oil and refined products—particularly through the Strait of Hormuz—resulting in logistical constraints and delays in project execution. The impact has been more pronounced in Reservoir Description due to its unique role in supporting regional client studies, crude oil assay testing, and reservoir rock and fluid characterization, all of which rely on predictable field access, sample movement, and laboratory operations. Production Enhancement has been comparatively less affected; however, shipments of energetics products into certain parts of the region have been delayed or temporarily suspended. Core's revised guidance for first quarter 2026 revenue ranges from $119,000,000to $123,000,000, while operating income, ex-items, is projected to range from $5,700,000to $7,100,000. The Company is now projecting Earnings Per Share, ex-items, to be between $0.05 to $0.07 for the first quarter of 2026.공시 • Mar 04Core Laboratories Inc. announced delayed annual 10-K filingOn 03/03/2026, Core Laboratories Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Feb 05Core Laboratories Inc. Approves a Cash Dividend, Payable on March 9, 2026On February 4, 2026, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock, payable on March 9, 2026, to shareholders of record on February 16, 2026.공시 • Jan 06Core Laboratories Inc. to Report Q4, 2025 Results on Feb 04, 2026Core Laboratories Inc. announced that they will report Q4, 2025 results After-Market on Feb 04, 2026공시 • Oct 23+ 1 more updateCore Laboratories Inc. Announces Earnings Guidance for Fourth Quarter 2025Core Laboratories Inc. announced earnings guidance for fourth quarter 2025. For the quarter, revenue is projected to range from $132,000,000 to $136,000,000, with operating income of $14,000,000 to $16,100,000, yielding operating margins of approximately 11%. EPS for the fourth quarter of 2025 is expected to be $0.18 to $0.22.공시 • Oct 01Core Laboratories Inc. (NYSE:CLB) acquired Solintec Consultoria E Servicos De Geologia Ltda.Core Laboratories Inc. (NYSE:CLB) acquired Solintec Consultoria E Servicos De Geologia Ltda on September 30, 2025. This acquisition will further enhance Core Lab’s presence to deliver the most comprehensive suite of reservoir laboratory services in the region and long-term, sustainable value for its clients and shareholders. Core Laboratories Inc. (NYSE:CLB) completed the acquisition of Solintec Consultoria E Servicos De Geologia Ltda on September 30, 2025.공시 • Sep 25Core Laboratories Inc. to Report Q3, 2025 Results on Oct 22, 2025Core Laboratories Inc. announced that they will report Q3, 2025 results After-Market on Oct 22, 2025공시 • Jul 24+ 1 more updateCore Laboratories Inc. Approves Cash Dividend, Payable on August 25, 2025On July 23, 2025, Core Laboratories Inc. Board approved a cash dividend of $0.01 per share of common stock payable on August 25, 2025, to shareholders of record on August 4, 2025.공시 • Jun 30+ 3 more updatesCore Laboratories Inc.(NYSE:CLB) dropped from Russell 2000 Growth IndexCore Laboratories Inc.(NYSE:CLB) dropped from Russell 2000 Growth Index공시 • Jun 25Core Laboratories Inc. to Report Q2, 2025 Results on Jul 23, 2025Core Laboratories Inc. announced that they will report Q2, 2025 results After-Market on Jul 23, 2025공시 • Apr 24Core Laboratories Inc. Approves Cash Dividend, Payable on May 27, 2025On April 23, 2025, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock payable on May 27, 2025, to shareholders of record on May 5, 2025.공시 • Apr 02Core Laboratories Inc., Annual General Meeting, May 21, 2025Core Laboratories Inc., Annual General Meeting, May 21, 2025. Location: at the hotel zaza, memorial city, 9787 katy freeway, texas 77024, houston, United States공시 • Mar 25Core Laboratories Inc. to Report Q1, 2025 Results on Apr 23, 2025Core Laboratories Inc. announced that they will report Q1, 2025 results at 4:00 PM, US Eastern Standard Time on Apr 23, 2025공시 • Jan 30+ 1 more updateCore Laboratories Inc. Provides Earnings Guidance for the First Quarter 2025Core Laboratories Inc. provided earnings revenue for the first quarter 2025. The Company's first quarter 2025 revenue is projected to range from $121,000,000 to $127,000,000, with operating income of $10,200,000 to $12,800,000, yielding operating margins of approximately 9%. As such, EPS for the first quarter of 2025 is expected to be $0.12 to $0.16.공시 • Jan 04Core Laboratories Inc. to Report Q4, 2024 Results on Jan 29, 2025Core Laboratories Inc. announced that they will report Q4, 2024 results After-Market on Jan 29, 2025Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €20.20, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 7x in the Energy Services industry in Europe. Total loss to shareholders of 14% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €25.65 per share.Declared Dividend • Oct 28Third quarter dividend of US$0.01 announcedShareholders will receive a dividend of US$0.01. Ex-date: 4th November 2024 Payment date: 25th November 2024 Dividend yield will be 0.2%, which is lower than the industry average of 2.7%. Payout Ratios Payout ratio: 7%. Cash payout ratio: 4%.Reported Earnings • Oct 24Third quarter 2024 earnings released: EPS: US$0.25 (vs US$0.20 in 3Q 2023)Third quarter 2024 results: EPS: US$0.25 (up from US$0.20 in 3Q 2023). Revenue: US$134.4m (up 7.2% from 3Q 2023). Net income: US$11.7m (up 27% from 3Q 2023). Profit margin: 8.7% (up from 7.4% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Energy Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.공시 • Oct 24+ 1 more updateCore Laboratories Inc. Provides Earnings Guidance for the Fourth Quarter of 2024Core Laboratories Inc. provided earnings guidance for the fourth quarter of 2024. The company’s fourth quarter 2024 revenue is projected to range from $128,500,000 to $135,500,000, with operating income of $14,800,000 to $17,700,000, yielding operating margins of approximately 12%. EPS for the fourth quarter of 2024 is expected to be $0.20 to $0.25.Buy Or Sell Opportunity • Oct 23Now 23% undervaluedThe stock has been flat over the last 90 days, currently trading at €15.90. The fair value is estimated to be €20.78, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 16%. Revenue is forecast to grow by 11% in 2 years. Earnings are forecast to grow by 123% in the next 2 years.공시 • Sep 25Core Laboratories Inc. to Report Q3, 2024 Results on Oct 23, 2024Core Laboratories Inc. announced that they will report Q3, 2024 results After-Market on Oct 23, 2024Buy Or Sell Opportunity • Aug 06Now 43% undervaluedThe stock has been flat over the last 90 days, currently trading at €12.30. The fair value is estimated to be €21.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 16%. For the next 3 years, revenue is forecast to grow by 4.5% per annum. Earnings are also forecast to grow by 20% per annum over the same time period.Upcoming Dividend • Jul 31Upcoming dividend of US$0.01 per shareEligible shareholders must have bought the stock before 05 August 2024. Payment date: 26 August 2024. Payout ratio is a comfortable 7.9% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (3.8%).Declared Dividend • Jul 31Second quarter dividend of US$0.01 announcedShareholders will receive a dividend of US$0.01. Ex-date: 5th August 2024 Payment date: 26th August 2024 Dividend yield will be 0.2%, which is lower than the industry average of 2.7%. Payout Ratios Payout ratio: 8%. Cash payout ratio: 6%.공시 • Jul 25+ 1 more updateCore Laboratories Inc. Approves Cash Dividend, Payable on August 26, 2024On July 24, 2024, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock payable on August 26, 2024 to shareholders of record on August 5, 2024.공시 • Jun 26Core Laboratories Inc. to Report Q2, 2024 Results on Jul 24, 2024Core Laboratories Inc. announced that they will report Q2, 2024 results After-Market on Jul 24, 2024Declared Dividend • Apr 29First quarter dividend of US$0.01 announcedShareholders will receive a dividend of US$0.01. Ex-date: 3rd May 2024 Payment date: 28th May 2024 Dividend yield will be 0.2%, which is lower than the industry average of 2.7%. Payout Ratios Payout ratio: 5%. Cash payout ratio: 9%.공시 • Apr 26Core Laboratories Inc. Approves Cash Dividend, Payable on May 28, 2024On April 24, 2024, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock payable on May 28, 2024 to shareholders of record on May 6, 2024.Reported Earnings • Apr 25First quarter 2024 earnings released: EPS: US$0.068 (vs US$0.051 in 1Q 2023)First quarter 2024 results: EPS: US$0.068 (up from US$0.051 in 1Q 2023). Revenue: US$129.6m (up 1.0% from 1Q 2023). Net income: US$3.22m (up 36% from 1Q 2023). Profit margin: 2.5% (up from 1.8% in 1Q 2023). Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 1.3% growth forecast for the Energy Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.공시 • Mar 26Core Laboratories Inc. to Report Q1, 2024 Results on Apr 24, 2024Core Laboratories Inc. announced that they will report Q1, 2024 results After-Market on Apr 24, 2024공시 • Mar 20Core Laboratories Inc., Annual General Meeting, May 08, 2024Core Laboratories Inc., Annual General Meeting, May 08, 2024, at 09:00 Central Daylight. Location: Hotel Zaza, Memorial City, 9787 Katy Freeway Houston Texas United States Agenda: To re-elect two current Class III Directors to serve under the terms and conditions described within the proxy statement until our annual meeting in 2027 and until their successors shall have been duly elected and qualified; to ratify the appointment of KPMG LLP as the Company's independent registered public accountants for the year ending December 31, 2024; to approve, on an advisory basis, the compensation philosophy, policies and procedures described in the section entitled Compensation Discussion and Analysis, and the compensation of the Company's named executive officers as disclosed pursuant to the U.S. Securities and Exchange Commission's compensation disclosure rules, including the compensation tables; and to discuss other matters.공시 • Feb 01+ 1 more updateCore Laboratories Inc. Approves Cash Dividend, Payable on March 4, 2024On January 31, 2024, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock payable on March 4, 2024 to shareholders of record on February 12, 2024.공시 • Nov 02+ 1 more updateCore Laboratories Inc. Provides Consolidated Earnings Guidance for the Fourth Quarter of 2023Core Laboratories Inc. provided consolidated earnings guidance for the fourth quarter of 2023. The company's fourth quarter 2023 revenue is projected to range from $125,000,000 to $132,000,000 and operating income of $13,800,000 to $17,300,000, yielding operating margins of approximately 12%. EPS for the fourth quarter of 2023 is expected to be $0.17 to $0.23. The Company's fourth quarter 2023 guidance is based on projections for underlying operations and excludes gains and losses in foreign exchange.공시 • Oct 05Core Laboratories Inc. to Report Q3, 2023 Results on Nov 01, 2023Core Laboratories Inc. announced that they will report Q3, 2023 results After-Market on Nov 01, 2023Reported Earnings • Jul 27Second quarter 2023 earnings released: EPS: US$0.49 (vs US$0.15 in 2Q 2022)Second quarter 2023 results: EPS: US$0.49 (up from US$0.15 in 2Q 2022). Revenue: US$127.9m (up 5.8% from 2Q 2022). Net income: US$22.8m (up 223% from 2Q 2022). Profit margin: 18% (up from 5.8% in 2Q 2022). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Energy Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.공시 • Jul 04Core Laboratories Inc. Approves to Elect Curtis Anastasio as Class I DirectorCore Laboratories Inc. announced at the AGM held on June 28, 2023 that the company approved to elect Curtis Anastasio as Class I Director.공시 • Jun 28Core Laboratories Inc. to Report Q2, 2023 Results on Jul 26, 2023Core Laboratories Inc. announced that they will report Q2, 2023 results After-Market on Jul 26, 2023이익 및 매출 성장 예측DB:HJ1 - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202754837N/AN/A212/31/202652121N/AN/A13/31/2026525291834N/A12/31/2025527302237N/A9/30/2025518323450N/A6/30/2025517303954N/A3/31/2025518284458N/A12/31/2024524314356N/A9/30/2024523264455N/A6/30/2024514243042N/A3/31/2024511382233N/A12/31/2023510371425N/A9/30/202350941919N/A6/30/2023510391525N/A3/31/202350324616N/A12/31/2022490191525N/A9/30/202248715619N/A6/30/202247991125N/A3/31/2022477102134N/A12/31/2021470202337N/A9/30/202145931518N/A6/30/2021446331526N/A3/31/2021443193244N/A12/31/2020487-974558N/A9/30/2020530-1017791N/A6/30/2020598-807996N/A3/31/2020651-556686N/A12/31/201966894N/A90N/A9/30/201968592N/A106N/A6/30/201969490N/A104N/A3/31/201970096N/A114N/A12/31/201870180N/A112N/A9/30/201869893N/A120N/A6/30/201867891N/A126N/A3/31/201866187N/A118N/A12/31/201764881N/A124N/A9/30/201762775N/A102N/A6/30/201760871N/A107N/A3/31/201759867N/A116N/A12/31/201659065N/A132N/A9/30/201662864N/A158N/A6/30/201668281N/A167N/A3/31/201673899N/A186N/A12/31/2015798115N/A219N/A9/30/2015893166N/A268N/A6/30/2015972199N/A299N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: HJ1 의 연간 예상 수익 증가율(18.3%)이 saving rate(1.9%)보다 높습니다.수익 vs 시장: HJ1 의 연간 수익(18.3%)이 German 시장(16.9%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: HJ1 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: HJ1 의 수익(연간 2.5%)이 German 시장(연간 6.8%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: HJ1 의 수익(연간 2.5%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: HJ1의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YEnergy 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 01:32종가2026/05/21 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Core Laboratories Inc.는 30명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관James WestBarclaysNicholas GreenBernsteinSaurabh PantBofA Global Research27명의 분석가 더 보기
공시 • Mar 24+ 1 more updateCore Laboratories Inc. Revises Earnings Guidance for the First Quarter 2026Core Laboratories Inc. revised earnings guidance for the first quarter 2026 . Company continues to evaluate and monitor the evolving geopolitical conflict in the Middle East and its effect on the Company's first quarter 2026 financial results. Core Lab is working with clients and its local teams to manage operations and mitigate impacts on project execution through a rapidly changing operating environment. The safety and security of the Company's employees remain its highest priority. At this time, due to regional instability, including client-driven project delays, travel constraints, and supply-chain disruptions, the Company expects first quarter 2026 revenue and earnings to be below its previously issued guidance provided on February 4, 2026. Changes in client activity levels across the Middle East are directly impacting operations in the countries where Core Lab operates. Damage to oil refining infrastructure and storage terminals has created capacity limitations, forcing operators to shut in or limit oil production. These effects have extended to regional supply chains and the maritime transportation of crude oil and refined products—particularly through the Strait of Hormuz—resulting in logistical constraints and delays in project execution. The impact has been more pronounced in Reservoir Description due to its unique role in supporting regional client studies, crude oil assay testing, and reservoir rock and fluid characterization, all of which rely on predictable field access, sample movement, and laboratory operations. Production Enhancement has been comparatively less affected; however, shipments of energetics products into certain parts of the region have been delayed or temporarily suspended. Core's revised guidance for first quarter 2026 revenue ranges from $119,000,000to $123,000,000, while operating income, ex-items, is projected to range from $5,700,000to $7,100,000. The Company is now projecting Earnings Per Share, ex-items, to be between $0.05 to $0.07 for the first quarter of 2026.
공시 • Oct 23+ 1 more updateCore Laboratories Inc. Announces Earnings Guidance for Fourth Quarter 2025Core Laboratories Inc. announced earnings guidance for fourth quarter 2025. For the quarter, revenue is projected to range from $132,000,000 to $136,000,000, with operating income of $14,000,000 to $16,100,000, yielding operating margins of approximately 11%. EPS for the fourth quarter of 2025 is expected to be $0.18 to $0.22.
공시 • Jan 30+ 1 more updateCore Laboratories Inc. Provides Earnings Guidance for the First Quarter 2025Core Laboratories Inc. provided earnings revenue for the first quarter 2025. The Company's first quarter 2025 revenue is projected to range from $121,000,000 to $127,000,000, with operating income of $10,200,000 to $12,800,000, yielding operating margins of approximately 9%. As such, EPS for the first quarter of 2025 is expected to be $0.12 to $0.16.
공시 • Oct 24+ 1 more updateCore Laboratories Inc. Provides Earnings Guidance for the Fourth Quarter of 2024Core Laboratories Inc. provided earnings guidance for the fourth quarter of 2024. The company’s fourth quarter 2024 revenue is projected to range from $128,500,000 to $135,500,000, with operating income of $14,800,000 to $17,700,000, yielding operating margins of approximately 12%. EPS for the fourth quarter of 2024 is expected to be $0.20 to $0.25.
공시 • Nov 02+ 1 more updateCore Laboratories Inc. Provides Consolidated Earnings Guidance for the Fourth Quarter of 2023Core Laboratories Inc. provided consolidated earnings guidance for the fourth quarter of 2023. The company's fourth quarter 2023 revenue is projected to range from $125,000,000 to $132,000,000 and operating income of $13,800,000 to $17,300,000, yielding operating margins of approximately 12%. EPS for the fourth quarter of 2023 is expected to be $0.17 to $0.23. The Company's fourth quarter 2023 guidance is based on projections for underlying operations and excludes gains and losses in foreign exchange.
공시 • May 02Core Laboratories Inc. Approves Cash Dividend, Payable on June 1, 2026Core Laboratories Inc. announced on April 29, 2026, the Board approved a cash dividend of $0.01 per share of common stock, payable on June 1, 2026, to shareholders of record on May 11, 2026.
공시 • Apr 01Core Laboratories Inc., Annual General Meeting, May 12, 2026Core Laboratories Inc., Annual General Meeting, May 12, 2026. Location: hotel zaza, memorial city, 9787 katy freeway, texas 77024, houston, United States
공시 • Mar 24+ 1 more updateCore Laboratories Inc. Revises Earnings Guidance for the First Quarter 2026Core Laboratories Inc. revised earnings guidance for the first quarter 2026 . Company continues to evaluate and monitor the evolving geopolitical conflict in the Middle East and its effect on the Company's first quarter 2026 financial results. Core Lab is working with clients and its local teams to manage operations and mitigate impacts on project execution through a rapidly changing operating environment. The safety and security of the Company's employees remain its highest priority. At this time, due to regional instability, including client-driven project delays, travel constraints, and supply-chain disruptions, the Company expects first quarter 2026 revenue and earnings to be below its previously issued guidance provided on February 4, 2026. Changes in client activity levels across the Middle East are directly impacting operations in the countries where Core Lab operates. Damage to oil refining infrastructure and storage terminals has created capacity limitations, forcing operators to shut in or limit oil production. These effects have extended to regional supply chains and the maritime transportation of crude oil and refined products—particularly through the Strait of Hormuz—resulting in logistical constraints and delays in project execution. The impact has been more pronounced in Reservoir Description due to its unique role in supporting regional client studies, crude oil assay testing, and reservoir rock and fluid characterization, all of which rely on predictable field access, sample movement, and laboratory operations. Production Enhancement has been comparatively less affected; however, shipments of energetics products into certain parts of the region have been delayed or temporarily suspended. Core's revised guidance for first quarter 2026 revenue ranges from $119,000,000to $123,000,000, while operating income, ex-items, is projected to range from $5,700,000to $7,100,000. The Company is now projecting Earnings Per Share, ex-items, to be between $0.05 to $0.07 for the first quarter of 2026.
공시 • Mar 04Core Laboratories Inc. announced delayed annual 10-K filingOn 03/03/2026, Core Laboratories Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Feb 05Core Laboratories Inc. Approves a Cash Dividend, Payable on March 9, 2026On February 4, 2026, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock, payable on March 9, 2026, to shareholders of record on February 16, 2026.
공시 • Jan 06Core Laboratories Inc. to Report Q4, 2025 Results on Feb 04, 2026Core Laboratories Inc. announced that they will report Q4, 2025 results After-Market on Feb 04, 2026
공시 • Oct 23+ 1 more updateCore Laboratories Inc. Announces Earnings Guidance for Fourth Quarter 2025Core Laboratories Inc. announced earnings guidance for fourth quarter 2025. For the quarter, revenue is projected to range from $132,000,000 to $136,000,000, with operating income of $14,000,000 to $16,100,000, yielding operating margins of approximately 11%. EPS for the fourth quarter of 2025 is expected to be $0.18 to $0.22.
공시 • Oct 01Core Laboratories Inc. (NYSE:CLB) acquired Solintec Consultoria E Servicos De Geologia Ltda.Core Laboratories Inc. (NYSE:CLB) acquired Solintec Consultoria E Servicos De Geologia Ltda on September 30, 2025. This acquisition will further enhance Core Lab’s presence to deliver the most comprehensive suite of reservoir laboratory services in the region and long-term, sustainable value for its clients and shareholders. Core Laboratories Inc. (NYSE:CLB) completed the acquisition of Solintec Consultoria E Servicos De Geologia Ltda on September 30, 2025.
공시 • Sep 25Core Laboratories Inc. to Report Q3, 2025 Results on Oct 22, 2025Core Laboratories Inc. announced that they will report Q3, 2025 results After-Market on Oct 22, 2025
공시 • Jul 24+ 1 more updateCore Laboratories Inc. Approves Cash Dividend, Payable on August 25, 2025On July 23, 2025, Core Laboratories Inc. Board approved a cash dividend of $0.01 per share of common stock payable on August 25, 2025, to shareholders of record on August 4, 2025.
공시 • Jun 30+ 3 more updatesCore Laboratories Inc.(NYSE:CLB) dropped from Russell 2000 Growth IndexCore Laboratories Inc.(NYSE:CLB) dropped from Russell 2000 Growth Index
공시 • Jun 25Core Laboratories Inc. to Report Q2, 2025 Results on Jul 23, 2025Core Laboratories Inc. announced that they will report Q2, 2025 results After-Market on Jul 23, 2025
공시 • Apr 24Core Laboratories Inc. Approves Cash Dividend, Payable on May 27, 2025On April 23, 2025, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock payable on May 27, 2025, to shareholders of record on May 5, 2025.
공시 • Apr 02Core Laboratories Inc., Annual General Meeting, May 21, 2025Core Laboratories Inc., Annual General Meeting, May 21, 2025. Location: at the hotel zaza, memorial city, 9787 katy freeway, texas 77024, houston, United States
공시 • Mar 25Core Laboratories Inc. to Report Q1, 2025 Results on Apr 23, 2025Core Laboratories Inc. announced that they will report Q1, 2025 results at 4:00 PM, US Eastern Standard Time on Apr 23, 2025
공시 • Jan 30+ 1 more updateCore Laboratories Inc. Provides Earnings Guidance for the First Quarter 2025Core Laboratories Inc. provided earnings revenue for the first quarter 2025. The Company's first quarter 2025 revenue is projected to range from $121,000,000 to $127,000,000, with operating income of $10,200,000 to $12,800,000, yielding operating margins of approximately 9%. As such, EPS for the first quarter of 2025 is expected to be $0.12 to $0.16.
공시 • Jan 04Core Laboratories Inc. to Report Q4, 2024 Results on Jan 29, 2025Core Laboratories Inc. announced that they will report Q4, 2024 results After-Market on Jan 29, 2025
Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €20.20, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 7x in the Energy Services industry in Europe. Total loss to shareholders of 14% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €25.65 per share.
Declared Dividend • Oct 28Third quarter dividend of US$0.01 announcedShareholders will receive a dividend of US$0.01. Ex-date: 4th November 2024 Payment date: 25th November 2024 Dividend yield will be 0.2%, which is lower than the industry average of 2.7%. Payout Ratios Payout ratio: 7%. Cash payout ratio: 4%.
Reported Earnings • Oct 24Third quarter 2024 earnings released: EPS: US$0.25 (vs US$0.20 in 3Q 2023)Third quarter 2024 results: EPS: US$0.25 (up from US$0.20 in 3Q 2023). Revenue: US$134.4m (up 7.2% from 3Q 2023). Net income: US$11.7m (up 27% from 3Q 2023). Profit margin: 8.7% (up from 7.4% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Energy Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
공시 • Oct 24+ 1 more updateCore Laboratories Inc. Provides Earnings Guidance for the Fourth Quarter of 2024Core Laboratories Inc. provided earnings guidance for the fourth quarter of 2024. The company’s fourth quarter 2024 revenue is projected to range from $128,500,000 to $135,500,000, with operating income of $14,800,000 to $17,700,000, yielding operating margins of approximately 12%. EPS for the fourth quarter of 2024 is expected to be $0.20 to $0.25.
Buy Or Sell Opportunity • Oct 23Now 23% undervaluedThe stock has been flat over the last 90 days, currently trading at €15.90. The fair value is estimated to be €20.78, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 16%. Revenue is forecast to grow by 11% in 2 years. Earnings are forecast to grow by 123% in the next 2 years.
공시 • Sep 25Core Laboratories Inc. to Report Q3, 2024 Results on Oct 23, 2024Core Laboratories Inc. announced that they will report Q3, 2024 results After-Market on Oct 23, 2024
Buy Or Sell Opportunity • Aug 06Now 43% undervaluedThe stock has been flat over the last 90 days, currently trading at €12.30. The fair value is estimated to be €21.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 16%. For the next 3 years, revenue is forecast to grow by 4.5% per annum. Earnings are also forecast to grow by 20% per annum over the same time period.
Upcoming Dividend • Jul 31Upcoming dividend of US$0.01 per shareEligible shareholders must have bought the stock before 05 August 2024. Payment date: 26 August 2024. Payout ratio is a comfortable 7.9% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (3.8%).
Declared Dividend • Jul 31Second quarter dividend of US$0.01 announcedShareholders will receive a dividend of US$0.01. Ex-date: 5th August 2024 Payment date: 26th August 2024 Dividend yield will be 0.2%, which is lower than the industry average of 2.7%. Payout Ratios Payout ratio: 8%. Cash payout ratio: 6%.
공시 • Jul 25+ 1 more updateCore Laboratories Inc. Approves Cash Dividend, Payable on August 26, 2024On July 24, 2024, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock payable on August 26, 2024 to shareholders of record on August 5, 2024.
공시 • Jun 26Core Laboratories Inc. to Report Q2, 2024 Results on Jul 24, 2024Core Laboratories Inc. announced that they will report Q2, 2024 results After-Market on Jul 24, 2024
Declared Dividend • Apr 29First quarter dividend of US$0.01 announcedShareholders will receive a dividend of US$0.01. Ex-date: 3rd May 2024 Payment date: 28th May 2024 Dividend yield will be 0.2%, which is lower than the industry average of 2.7%. Payout Ratios Payout ratio: 5%. Cash payout ratio: 9%.
공시 • Apr 26Core Laboratories Inc. Approves Cash Dividend, Payable on May 28, 2024On April 24, 2024, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock payable on May 28, 2024 to shareholders of record on May 6, 2024.
Reported Earnings • Apr 25First quarter 2024 earnings released: EPS: US$0.068 (vs US$0.051 in 1Q 2023)First quarter 2024 results: EPS: US$0.068 (up from US$0.051 in 1Q 2023). Revenue: US$129.6m (up 1.0% from 1Q 2023). Net income: US$3.22m (up 36% from 1Q 2023). Profit margin: 2.5% (up from 1.8% in 1Q 2023). Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 1.3% growth forecast for the Energy Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
공시 • Mar 26Core Laboratories Inc. to Report Q1, 2024 Results on Apr 24, 2024Core Laboratories Inc. announced that they will report Q1, 2024 results After-Market on Apr 24, 2024
공시 • Mar 20Core Laboratories Inc., Annual General Meeting, May 08, 2024Core Laboratories Inc., Annual General Meeting, May 08, 2024, at 09:00 Central Daylight. Location: Hotel Zaza, Memorial City, 9787 Katy Freeway Houston Texas United States Agenda: To re-elect two current Class III Directors to serve under the terms and conditions described within the proxy statement until our annual meeting in 2027 and until their successors shall have been duly elected and qualified; to ratify the appointment of KPMG LLP as the Company's independent registered public accountants for the year ending December 31, 2024; to approve, on an advisory basis, the compensation philosophy, policies and procedures described in the section entitled Compensation Discussion and Analysis, and the compensation of the Company's named executive officers as disclosed pursuant to the U.S. Securities and Exchange Commission's compensation disclosure rules, including the compensation tables; and to discuss other matters.
공시 • Feb 01+ 1 more updateCore Laboratories Inc. Approves Cash Dividend, Payable on March 4, 2024On January 31, 2024, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock payable on March 4, 2024 to shareholders of record on February 12, 2024.
공시 • Nov 02+ 1 more updateCore Laboratories Inc. Provides Consolidated Earnings Guidance for the Fourth Quarter of 2023Core Laboratories Inc. provided consolidated earnings guidance for the fourth quarter of 2023. The company's fourth quarter 2023 revenue is projected to range from $125,000,000 to $132,000,000 and operating income of $13,800,000 to $17,300,000, yielding operating margins of approximately 12%. EPS for the fourth quarter of 2023 is expected to be $0.17 to $0.23. The Company's fourth quarter 2023 guidance is based on projections for underlying operations and excludes gains and losses in foreign exchange.
공시 • Oct 05Core Laboratories Inc. to Report Q3, 2023 Results on Nov 01, 2023Core Laboratories Inc. announced that they will report Q3, 2023 results After-Market on Nov 01, 2023
Reported Earnings • Jul 27Second quarter 2023 earnings released: EPS: US$0.49 (vs US$0.15 in 2Q 2022)Second quarter 2023 results: EPS: US$0.49 (up from US$0.15 in 2Q 2022). Revenue: US$127.9m (up 5.8% from 2Q 2022). Net income: US$22.8m (up 223% from 2Q 2022). Profit margin: 18% (up from 5.8% in 2Q 2022). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Energy Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
공시 • Jul 04Core Laboratories Inc. Approves to Elect Curtis Anastasio as Class I DirectorCore Laboratories Inc. announced at the AGM held on June 28, 2023 that the company approved to elect Curtis Anastasio as Class I Director.
공시 • Jun 28Core Laboratories Inc. to Report Q2, 2023 Results on Jul 26, 2023Core Laboratories Inc. announced that they will report Q2, 2023 results After-Market on Jul 26, 2023